Methods of preventing, reducing or treating macular degeneration
CA2902888A1
A method of providing ocular neuroprotection
BR112015021870A2
Ophthalmic formulations
MX2014009086A
Anhydrous polymorphs of (2r,3s,4r,5r)-5-(6-(cyclopentylamino)-9h- purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl) } methyl nitrate and processes of preparation thereof.
CN102933593A
Method of reducing intraocular pressure in humans using n6-cyclopentyladenosine (cpa), cpa derivatives or prodrugs thereof
CN102822188A
Adenosine compounds and their use thereof
CN102933220A
Combination compositions of adenosine a1 agonists and carbonic anhydrase inhibitors for reducing intraocular pressure
ME02594B
Combination compositions of adenosine a1 agonists and non-selective beta-adrenergic receptor blockers for reducing intraocular pressure
SG10201502588UA
Combination, kit and method of reducing intraocular pressure
NZ700629A
Combination, kit and method of reducing intraocular pressure
BR112012009841A2
ophthalmic formulation and process for its preparation
RS54378B1
Method of reducing intraocular pressure in humans
US2010239583A1
Antibodies against flagellin and uses thereof
US2010261706A1
Substituted tetracyclic 1h-indeno [1,2-b]pyridine-2(5h)-one analogs thereof and uses thereof
US2009257999A1
Method of preventing contrast-induced nephropathy
WO2009033009A2
Antibodies against flagellin and uses thereof
CA2677046A1
Indenoisoquinolinone analogs and methods of use thereof
CN101404883A
Purine compounds and methods of use thereof
AU2007229463A1
Purine compounds and methods of use thereof
WO2007117289A2
Methods for treating or preventing erectile dysfunction or urinary incontinence
